Navigation Links
ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
Date:4/1/2008

="http://www.istavision.com" target="_new">http://www.istavision.com.

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to the completion of the data analysis and discussions with the FDA regarding the Xibrom QD NDA or possible new Xibrom products and the possibility of a label change for the currently marketed 0.09% formulation of Xibrom, bringing a new product to market every 12 to 18 months, and becoming the leading niche ophthalmic pharmaceutical company are forward- looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including the difficulty of predicting the timing or outcome of product development efforts and the FDA or other regulatory agency approval or actions); uncertainties and risks regarding market acceptance of and demand for ISTA's approved products and the impact of competitive products and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertai
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
3. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
4. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
7. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
8. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
9. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
10. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
11. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
(Date:9/22/2014)... 2014  Aethlon Medical, Inc. (OTCQB: AEMD), the ... infectious disease, cancer and other life-threatening conditions, disclosed ... (DARPA) has informed the Company that it plans ... four of a five-year $5.9 million contract that ... under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
(Date:9/22/2014)... , Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: CUR) ... investigator at Emory University, presented long-term follow up data ... stem cells in the treatment of amyotrophic lateral sclerosis ... which occurred at the Annual Symposium on ALS of ... , on Friday, and was not open to the ...
Breaking Medicine Technology:Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4
... One out of three U.S. adults plan to skip ... Medical telephone poll. Against that backdrop, two top clinical leaders ... American public that influenza season can be a deadly time ... asthma or COPD (Chronic Obstructive Pulmonary Disease). Such patients need ...
... One week after a CDC report outlined the devastating ... which causes 8,000 U.S. deaths and costs billions of ... of patients, families, advocates, physicians and scientists, last night ... discoveries and unique contributions to the field of dermatology ...
Cached Medicine Technology:Poll: One Out of Three U.S. Adults Not Planning to Get Flu Shot This Year 2American Skin Association Honors Leading Physicians and Scientists; Journalist Deborah Norville 2American Skin Association Honors Leading Physicians and Scientists; Journalist Deborah Norville 3
(Date:9/22/2014)... IsoComforter, Inc., one of the Nation’s premier ... of an innovative IsoTube technology and uniflow technology that ... ridges provide optimal contact and pain control. By utilizing ... fluid reservoir to a pad that is applied to ... continuous cold therapy for an extended period of time ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Follow ... diagnostic procedure that provides quantitative measurement of bone density ... is driven by the rapidly aging world population, and ... The elderly represent potential candidates for measurement of bone ... of bone tissue as a result of the natural ...
(Date:9/22/2014)... the proverbial needle in the cancer antigen haystack, according ... of Experimental Medicine . , As cancer ... creates new versions of proteins, some of which are ... cells, prompting the cells to attack and eliminate the ... of the mutations in a patient,s cancer and to ...
(Date:9/22/2014)... Researchers have found that environment has a much ... a severe, often painful food allergy that renders ... foods. , Eosinophils are normal cellular components ... too many eosinophils they can cause a variety ... inflammation and resulting tissue damage, often in the ...
(Date:9/22/2014)... to be an old acquaintance: a certain module of ... considered an anchor protein. The researchers report their findings ... importing enzymes into peroxisome , Peroxisomes are of ... acids and cellular toxins. In order for them to ... imported into the peroxisomes first. The bulk is brought ...
Breaking Medicine News(10 mins):Health News:IsoComforter Cold Therapy Introduces Innovative IsoTube Technology 2Health News:Rising Incidence of Osteoporosis Spurs Growth in the Global Bone Densitometers Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Osteoporosis Spurs Growth in the Global Bone Densitometers Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Environment plays bigger role than genetics in food allergic disease eosinophilic esophagitis 2Health News:The accelerator of molecular motors 2
... scientists at the Johns Hopkins School of Public Health has ... called for urgent research into the impact of soya on ... in soya can damage the male reproductive organs. Though there ... on humans, its effects on rats were so severe that// ...
... a study published in the British Medical Journal, older people ... The researchers from Cambridge, UK, identified a group of 2,686 ... sent either one capsule of Vitamin D3 or a placebo ... to provide them with information on bone fractures// and any ...
... prevalent diseases in our society with more than five million ... According to a major study in the UK, in which ... across the UK, asthma sufferers are dying needlessly because they ... compared levels of asthma control and the need and number ...
... reached epidemic proportions the world over, with India being ... the many serious diseases that diabetics can be affected ... deterioration of nerves in the body. A diabetic patient ... one or more amputations. It has been found that ...
... appetite control, called ghrelin, has been identified by researchers ... demonstrated the effect of the hormone on the brain ... neurons in the hypothalamus involved in weight regulation. Ghrelin ... ability to stimulate feeding when introduced to specialized weight ...
... skin cancer and it has been shown through previous research ... whose UV rays cause damage to DNA that triggers cancer. ... more prone than others to melanoma. Researchers have now found ... with melanoma that those with fair skin// have lowered DNA ...
Cached Medicine News:Health News:Scientists locate key hormone involved in appetite control 2
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTT/1P chairs are recommended for the ... room, static control, health care and ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... ergonomic chairs with concave seats ... support • Select options like ... and glides. • BTT/1P chairs ... environments: industry, education, laboratory, clean ...
Medicine Products: